Bioequivalence testing to be made compulsory for capecitabine generics
Published: 2010-04-19 06:57:00
Updated: 2010-04-19 06:57:00
Local drug manufacturers who intend to obtain the product license for a generic version of capecitabine will be required to conduct bioequivalence testing instead of comparative dissolution test, according to the Korea Food and Drug Administration.
A KFDA official said that the safety and effi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
